Literature DB >> 26135075

Surgical Treatments of Tumor-Induced Osteomalacia Lesions in Long Bones: Seventeen Cases with More Than One Year of Follow-up.

Hai Wang1, Dingrong Zhong1, Yong Liu1, Yan Jiang1, Guixing Qiu1, Xisheng Weng1, Xiaoping Xing1, Mei Li1, Xunwu Meng1, Fang Li1, Zhaohui Zhu1, Wei Yu1, Weibo Xia1, Jin Jin1.   

Abstract

BACKGROUND: Tumor-induced osteomalacia is a rare and fascinating paraneoplastic syndrome usually caused by a small, benign phosphaturic mesenchymal tumor. Most tumors are treated surgically, but we are unaware of any reports that compare the results of curettage and segmental resection for lesions in long bones.
METHODS: Seventeen patients (ten male and seven female) with tumor-induced osteomalacia lesions in long bones, who underwent surgical treatment from December 2004 to August 2013 in our hospital, were included in this retrospective study. The mean follow-up (and standard deviation) was 35 ± 27 months (range, twelve to 116 months). The characteristics of the tumor and the effects of different surgical treatments (curettage compared with segmental resection) were evaluated.
RESULTS: All patients showed typical clinical characteristics of tumor-induced osteomalacia, including elevated serum fibroblast growth factor-23 (FGF-23); 82% of tumors were in the epiphysis, and 82% grew eccentrically. The mean maximum diameter of the tumors was 2.4 ± 2.0 cm. The complete resection rates were similar for curettage (67%) and segmental resection (80%). However, the recurrence rate after curettage (50%) was higher than that after segmental resection (0%). The complete resection rate for secondary segmental resection (75%) was not different from that for primary segmental resection (83%). All of our cases of tumor-induced osteomalacia were caused by phosphaturic mesenchymal tumors. After successful removal of tumors, serum FGF-23 returned to normal within twenty-four hours and serum phosphorus levels returned to normal at a mean of 6.5 ± 3.5 days.
CONCLUSIONS: Most lesions in long bones are located in the epiphysis, so curettage is first suggested to maintain joint function. If curettage is incomplete or there is a recurrence, secondary segmental resection should be considered curative. Changes of serum FGF-23 and phosphorus levels before and after the operation may be of prognostic help.
Copyright © 2015 by The Journal of Bone and Joint Surgery, Incorporated.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26135075     DOI: 10.2106/JBJS.N.01299

Source DB:  PubMed          Journal:  J Bone Joint Surg Am        ISSN: 0021-9355            Impact factor:   5.284


  6 in total

1.  [Hypophosphatemic osteomalacia caused by urinary mesenchymal tumor: A case report].

Authors:  H Wei; R Liu; Z H Wang; Z Q Yao
Journal:  Beijing Da Xue Xue Bao Yi Xue Ban       Date:  2019-12-18

Review 2.  Phosphaturic mesenchymal tumors: what an endocrinologist should know.

Authors:  J M Boland; P J Tebben; A L Folpe
Journal:  J Endocrinol Invest       Date:  2018-02-14       Impact factor: 4.256

3.  Total hip/knee arthroplasty in the treatment of tumor-induced osteomalacia patients: More than 1 year follow-up.

Authors:  Wei Zhu; Qi Ma; Yanyan Bian; Qianyu Zhuang; Zenan Xia; Jin Jin; Xisheng Weng
Journal:  PLoS One       Date:  2017-05-17       Impact factor: 3.240

4.  Mutational landscape and genetic signatures of cell-free DNA in tumour-induced osteomalacia.

Authors:  Nan Wu; Zhen Zhang; Xi Zhou; Hengqiang Zhao; Yue Ming; Xue Wu; Xian Zhang; Xin-Zhuang Yang; Meng Zhou; Hua Bao; Weisheng Chen; Yong Wu; Sen Liu; Huizi Wang; Yuchen Niu; Yalun Li; Yu Zheng; Yang Shao; Na Gao; Ying Yang; Ying Liu; Wenli Li; Jia Liu; Na Zhang; Xu Yang; Yuan Xu; Mei Li; Yingli Sun; Jianzhong Su; Jianguo Zhang; Weibo Xia; Guixing Qiu; Yong Liu; Jiaqi Liu; Zhihong Wu
Journal:  J Cell Mol Med       Date:  2020-04-11       Impact factor: 5.310

5.  Tumor-induced osteomalacia with the culprit lesion located in the palm: a case report.

Authors:  Yanying Qian; Zhijuan Dai; Cong Zhu; Luya Ruan; Saroj Thapa; Chaoming Wu
Journal:  J Int Med Res       Date:  2019-03-12       Impact factor: 1.671

Review 6.  Tumour-induced osteomalacia: a literature review and a case report.

Authors:  Jolanta Dadoniene; Marius Miglinas; Dalia Miltiniene; Donatas Vajauskas; Dmitrij Seinin; Petras Butenas; Tomas Kacergius
Journal:  World J Surg Oncol       Date:  2016-01-08       Impact factor: 2.754

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.